This is a translation of the original article in Portuguese. Read the original (Português).
A clinical trial presented in the United States showed that semaglutide, the active ingredient in so-called weight-loss pens, reduced obesity in children aged 6 to 11. Nearly 40% of participants were no longer classified as obese after 68 weeks of treatment, according to the Brazilian newspaper O Globo.
The results were released at the Obesity Week conference in the United States. The manufacturer Novo Nordisk, which makes Wegovy, has asked the FDA, the U.S. Food and Drug Administration, to approve the drug for this age group.
Use of these medications in young children, however, is far from consensus. According to O Globo, the medical community remains divided, and the World Health Organization (WHO) urges caution and has warned against use in children under 10. The trial covers children starting at age 6, the group where the WHO warning is most relevant.
What the study shows is that the drug was effective in reducing obesity over a period of 68 weeks. What it does not resolve is the debate over use in young children, which is the point of resistance for some doctors and for the WHO itself.
If the FDA approves the request, the treatment could become available to families and considered by health insurers in the United States. In Brazil, no decision has been made: any indication for children would depend on review by Anvisa, the national health regulatory agency that oversees medicines, and, if health plans were to cover it, by ANS, the national agency that regulates private health insurance, which would still have to rule on a request of this kind.
For Brazilian families, for now, the study serves as a signal of a debate that is likely to reach the country, not as an immediate change in the treatment of childhood obesity.
Reporting from O Globo (p. 25, Estados Unidos: Canetas emagrecedoras são eficazes contra obesidade infantil, diz estudo [jornal]), O Globo (p. 23, Estados Unidos: Estudo indica eficácia de canetas emagrecedoras em crianças [jornal]).
Deixe um comentário